Direct acting antiviral treatment of chronic hepatitis C in Denmark: factors associated with and barriers to treatment initiation

Christina Sølund; Sofie Hallager; Martin S Pedersen; Ulrik Fahnøe; Anja Ernst; Henrik B Krarup; Birgit T Røge; Peer B Christensen; Alex L Laursen; Jan Gerstoft; Erika Bélard; Lone G Madsen; Kristian Schønning; Anders G Pedersen; Jens Bukh; Nina Weis; DANHEP Group

doi:10.1080/00365521.2018.1467963

Direct acting antiviral treatment of chronic hepatitis C in Denmark: factors associated with and barriers to treatment initiation

Christina Sølund, Sofie Hallager, Martin S Pedersen, Ulrik Fahnøe, Anja Ernst, Henrik B Krarup, Birgit T Røge, Peer B Christensen, Alex L Laursen, Jan Gerstoft, Erika Bélard, Lone G Madsen, Kristian Schønning, Anders G Pedersen, Jens Bukh, Nina Weis, DANHEP Group

Department of Clinical Medicine

8 Citations (Scopus)

Abstract

OBJECTIVES: We describe factors associated with and barriers to initiation of Direct Acting Antiviral (DAA) treatment in patients with chronic hepatitis C, who fulfill national fibrosis treatment guidelines in Denmark.

MATERIALS AND METHODS: In this nationwide cohort study, we included patients with chronic hepatitis C from The Danish Database for Hepatitis B and C (DANHEP) who fulfilled fibrosis treatment criteria. Factors associated with treatment initiation and treatment failure were determined by logistic regression analyses. Medical records were reviewed from patients who fulfilled fibrosis treatment criteria, but did not initiate DAA treatment to determine the cause.

RESULTS: In 344 (49%) of 700 patients, who fulfilled treatment criteria, factors associated with DAA treatment initiation were transmission by other routes than injecting drug use odds ratio (OR) 2.13 (CI: 1.38-3.28), previous treatment failure OR 2.58 (CI: 1.84-3.61) and ALT above upper limit of normal OR 1.60 (CI: 1.18-2.17). The most frequent reasons for not starting treatment among 356 (51%) patients were non-adherence to medical appointments (n = 107/30%) and ongoing substance use (n = 61/17%). Treatment failure with viral relapse occurred in 19 (5.5%) patients, who were more likely to have failed previous treatment OR 4.53 (CI: 1.59-12.91).

CONCLUSIONS: In this nationwide cohort study, we found non-adherence to medical appointments and active substance use to be major obstacles for DAA treatment initiation. Our findings highlight the need for interventions that can overcome these barriers and increase the number of patients who can initiate and benefit from curative DAA treatment.

Original language	English
Journal	Scandinavian Journal of Gastroenterology
Volume	53
Issue number	7
Pages (from-to)	849-856
Number of pages	8
ISSN	0036-5521
DOIs	https://doi.org/10.1080/00365521.2018.1467963
Publication status	Published - 3 Jul 2018

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1080/00365521.2018.1467963

Cite this

Sølund, C., Hallager, S., Pedersen, M. S., Fahnøe, U., Ernst, A., Krarup, H. B., Røge, B. T., Christensen, P. B., Laursen, A. L., Gerstoft, J., Bélard, E., Madsen, L. G., Schønning, K., Pedersen, A. G., Bukh, J., Weis, N., & DANHEP Group (2018). Direct acting antiviral treatment of chronic hepatitis C in Denmark: factors associated with and barriers to treatment initiation. Scandinavian Journal of Gastroenterology, 53(7), 849-856. https://doi.org/10.1080/00365521.2018.1467963

Direct acting antiviral treatment of chronic hepatitis C in Denmark: factors associated with and barriers to treatment initiation. / Sølund, Christina; Hallager, Sofie; Pedersen, Martin S et al.
In: Scandinavian Journal of Gastroenterology, Vol. 53, No. 7, 03.07.2018, p. 849-856.

Research output: Contribution to journal › Journal article › Research › peer-review

Sølund, C, Hallager, S, Pedersen, MS, Fahnøe, U, Ernst, A, Krarup, HB, Røge, BT, Christensen, PB, Laursen, AL, Gerstoft, J, Bélard, E, Madsen, LG , Schønning, K, Pedersen, AG, Bukh, J , Weis, N & DANHEP Group 2018, 'Direct acting antiviral treatment of chronic hepatitis C in Denmark: factors associated with and barriers to treatment initiation', Scandinavian Journal of Gastroenterology, vol. 53, no. 7, pp. 849-856. https://doi.org/10.1080/00365521.2018.1467963

@article{061d24ad11494f8b8afded77fd835bf4,

title = "Direct acting antiviral treatment of chronic hepatitis C in Denmark: factors associated with and barriers to treatment initiation",

abstract = "OBJECTIVES: We describe factors associated with and barriers to initiation of Direct Acting Antiviral (DAA) treatment in patients with chronic hepatitis C, who fulfill national fibrosis treatment guidelines in Denmark.MATERIALS AND METHODS: In this nationwide cohort study, we included patients with chronic hepatitis C from The Danish Database for Hepatitis B and C (DANHEP) who fulfilled fibrosis treatment criteria. Factors associated with treatment initiation and treatment failure were determined by logistic regression analyses. Medical records were reviewed from patients who fulfilled fibrosis treatment criteria, but did not initiate DAA treatment to determine the cause.RESULTS: In 344 (49%) of 700 patients, who fulfilled treatment criteria, factors associated with DAA treatment initiation were transmission by other routes than injecting drug use odds ratio (OR) 2.13 (CI: 1.38-3.28), previous treatment failure OR 2.58 (CI: 1.84-3.61) and ALT above upper limit of normal OR 1.60 (CI: 1.18-2.17). The most frequent reasons for not starting treatment among 356 (51%) patients were non-adherence to medical appointments (n = 107/30%) and ongoing substance use (n = 61/17%). Treatment failure with viral relapse occurred in 19 (5.5%) patients, who were more likely to have failed previous treatment OR 4.53 (CI: 1.59-12.91).CONCLUSIONS: In this nationwide cohort study, we found non-adherence to medical appointments and active substance use to be major obstacles for DAA treatment initiation. Our findings highlight the need for interventions that can overcome these barriers and increase the number of patients who can initiate and benefit from curative DAA treatment.",

author = "Christina S{\o}lund and Sofie Hallager and Pedersen, {Martin S} and Ulrik Fahn{\o}e and Anja Ernst and Krarup, {Henrik B} and R{\o}ge, {Birgit T} and Christensen, {Peer B} and Laursen, {Alex L} and Jan Gerstoft and Erika B{\'e}lard and Madsen, {Lone G} and Kristian Sch{\o}nning and Pedersen, {Anders G} and Jens Bukh and Nina Weis and {DANHEP Group}",

year = "2018",

month = jul,

day = "3",

doi = "10.1080/00365521.2018.1467963",

language = "English",

volume = "53",

pages = "849--856",

journal = "Scandinavian Journal of Gastroenterology",

issn = "0036-5521",

publisher = "Taylor & Francis",

number = "7",

}

TY - JOUR

T1 - Direct acting antiviral treatment of chronic hepatitis C in Denmark

T2 - factors associated with and barriers to treatment initiation

AU - Sølund, Christina

AU - Hallager, Sofie

AU - Pedersen, Martin S

AU - Fahnøe, Ulrik

AU - Ernst, Anja

AU - Krarup, Henrik B

AU - Røge, Birgit T

AU - Christensen, Peer B

AU - Laursen, Alex L

AU - Gerstoft, Jan

AU - Bélard, Erika

AU - Madsen, Lone G

AU - Schønning, Kristian

AU - Pedersen, Anders G

AU - Bukh, Jens

AU - Weis, Nina

AU - DANHEP Group

PY - 2018/7/3

Y1 - 2018/7/3

N2 - OBJECTIVES: We describe factors associated with and barriers to initiation of Direct Acting Antiviral (DAA) treatment in patients with chronic hepatitis C, who fulfill national fibrosis treatment guidelines in Denmark.MATERIALS AND METHODS: In this nationwide cohort study, we included patients with chronic hepatitis C from The Danish Database for Hepatitis B and C (DANHEP) who fulfilled fibrosis treatment criteria. Factors associated with treatment initiation and treatment failure were determined by logistic regression analyses. Medical records were reviewed from patients who fulfilled fibrosis treatment criteria, but did not initiate DAA treatment to determine the cause.RESULTS: In 344 (49%) of 700 patients, who fulfilled treatment criteria, factors associated with DAA treatment initiation were transmission by other routes than injecting drug use odds ratio (OR) 2.13 (CI: 1.38-3.28), previous treatment failure OR 2.58 (CI: 1.84-3.61) and ALT above upper limit of normal OR 1.60 (CI: 1.18-2.17). The most frequent reasons for not starting treatment among 356 (51%) patients were non-adherence to medical appointments (n = 107/30%) and ongoing substance use (n = 61/17%). Treatment failure with viral relapse occurred in 19 (5.5%) patients, who were more likely to have failed previous treatment OR 4.53 (CI: 1.59-12.91).CONCLUSIONS: In this nationwide cohort study, we found non-adherence to medical appointments and active substance use to be major obstacles for DAA treatment initiation. Our findings highlight the need for interventions that can overcome these barriers and increase the number of patients who can initiate and benefit from curative DAA treatment.

AB - OBJECTIVES: We describe factors associated with and barriers to initiation of Direct Acting Antiviral (DAA) treatment in patients with chronic hepatitis C, who fulfill national fibrosis treatment guidelines in Denmark.MATERIALS AND METHODS: In this nationwide cohort study, we included patients with chronic hepatitis C from The Danish Database for Hepatitis B and C (DANHEP) who fulfilled fibrosis treatment criteria. Factors associated with treatment initiation and treatment failure were determined by logistic regression analyses. Medical records were reviewed from patients who fulfilled fibrosis treatment criteria, but did not initiate DAA treatment to determine the cause.RESULTS: In 344 (49%) of 700 patients, who fulfilled treatment criteria, factors associated with DAA treatment initiation were transmission by other routes than injecting drug use odds ratio (OR) 2.13 (CI: 1.38-3.28), previous treatment failure OR 2.58 (CI: 1.84-3.61) and ALT above upper limit of normal OR 1.60 (CI: 1.18-2.17). The most frequent reasons for not starting treatment among 356 (51%) patients were non-adherence to medical appointments (n = 107/30%) and ongoing substance use (n = 61/17%). Treatment failure with viral relapse occurred in 19 (5.5%) patients, who were more likely to have failed previous treatment OR 4.53 (CI: 1.59-12.91).CONCLUSIONS: In this nationwide cohort study, we found non-adherence to medical appointments and active substance use to be major obstacles for DAA treatment initiation. Our findings highlight the need for interventions that can overcome these barriers and increase the number of patients who can initiate and benefit from curative DAA treatment.

U2 - 10.1080/00365521.2018.1467963

DO - 10.1080/00365521.2018.1467963

M3 - Journal article

C2 - 29720023

SN - 0036-5521

VL - 53

SP - 849

EP - 856

JO - Scandinavian Journal of Gastroenterology

JF - Scandinavian Journal of Gastroenterology

IS - 7

ER -

Direct acting antiviral treatment of chronic hepatitis C in Denmark: factors associated with and barriers to treatment initiation

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this